Get trained in the latest innovations in vaccinology
Your training in Europe thanks to the Erasmus+ program
Call for application for 2024-25 (M2, 1-year) and 2024-26 (M1+M2, 2-year) programs
MyLIVE opens from Nov 15, 2023 to Jan 19, 2024 to apply for the Master LIVE, international vaccinology, Sept 2024 intake
MOTIVATED? Please visit Application > HOW TO APPLY
The Erasmus Mundus Joint Master “Leading International Vaccinology Education” (EMJM LIVE) is organized by a consortium of 60 associated partners and 5 full partner universities awarding the Master degree:
The Leading International Vaccinology Education (LIVE) Master of Science is a two-year programme that provides students with an advanced understanding of immunology, immunopathology, infectiology, vaccine-targeted diseases, vaccinology, and related legislation, health policy and humanities.
LIVE is a joint degree structured by five European universities located in Spain, Belgium and France. At the end of the programme, students will become master’s graduates and will have improved at least two foreign languages alongside their scientific studies. LIVE equips students with the scientific and multidisciplinary skills and knowledge required to start their professional journey in the vaccinology work chain, employed in academic research, big pharma vaccine manufacturers, small and medium-sized companies specialised in vaccine R&D, or institutions dealing with public health.
Erasmus Mundus Joint Master Label
European Commission recognizes the LIVE Master as an Erasmus Mundus Joint Master (EMJM) program of "outstanding academic quality".
The EMJM label allowed LIVE to grant scholarships to the majority of the European and non-European students admitted to the program. The label is active from 2016 to 2024, with extension to 2027, according to the reporting quality. LIVE is applying for renewed support with scholarships from the Erasmus+ Program of the European Union, for the period 2024-2029.
Furthermore, LIVE boasts a worldwide network of over 60 partner institutions, including academic universities from Brazil, China, Europe and USA, big pharma companies, small and medium enterprises and public health organisations.